Lecap Asset Management »

Halozyme Therapeutics shares owned by Lecap Asset Management

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Lecap Asset Management from 13F filings

Historical chart of Lecap Asset Management investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Lecap Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Lecap Asset Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $584k 8.0k 73.34

More positions owned by Lecap Asset Management

NVIDIA Corporation (NVDA)
TJX Companies (TJX)
Crown Castle Intl (CCI)
Marsh & McLennan Companies (MMC)
Charles Schwab Corporation (SCHW)
Sprouts Fmrs Mkt (SFM)
Tradeweb Mkts Cl A (TW)
Texas Instruments Incorporated (TXN)
Colgate-Palmolive Company (CL)
Ferguson Enterprises Common Stock New (FERG)
Broadridge Financial Solutions (BR)
Qorvo (QRVO)
Equitable Holdings (EQH)
Allstate Corporation (ALL)
Western Digital (WDC)

View all positions for Lecap Asset Management

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Arrowstreet Capital, Limited Partnership
Invesco
UBS Group
Snyder Capital Management
D. E. Shaw & Co
Geode Capital Management
Dimensional Fund Advisors
Alliancebernstein
Morgan Stanley
Macquarie Group
Federated Investors
Congress Asset Management

View all funds holding Halozyme Therapeutics